Search results
Results from the WOW.Com Content Network
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
Tissue-agnostic cancer drugs are antineoplastic drugs that treat cancers based on the mutations that they display, instead of the tissue type in which they appear. [ 1 ] [ 2 ] [ 3 ] Tissue-agnostic drugs that have been approved for medical use include Pembrolizumab , Larotrectinib , Selpercatinib , Entrectinib , and Pralsetinib .
An endothelin receptor antagonist (ERA) is a drug that blocks endothelin receptors. Three main kinds of ERAs exist: Dual ET Receptor Antagonists, which affect both endothelin A (ET A) and B receptors (ET B) [1] aprocitentan, bosentan, macitentan, tezosentan; Selective ET A Receptor Antagonists, which affect endothelin A receptors
A lower incidence of hypothyroidism was observed in a trial of combined B cell depletion and immune checkpoint inhibitor treatment compared with studies of immune checkpoint inhibitor monotherapy. [30] This holds promise for combining check point inhibitor therapy with immunosuppressive drugs to achieve anti-cancer effects with less toxicity.
Patients and their diseases are profiled in order to identify the most effective treatment for their specific case. Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, [1] others being hormonal therapy and cytotoxic chemotherapy.
Rucaparib, sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent. [2] Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). It is taken by mouth. [2] [4]
A MEK inhibitor is a chemical or drug that inhibits the mitogen-activated protein kinase enzymes MEK1 and/or MEK2.They can be used to affect the MAPK/ERK pathway which is often overactive in some cancers.
Lomustine is an alkylating chemotherapy drug that is indicated by the FDA for the treatment of patients with brain tumors (primary and metastatic), following any necessary surgery and radiation, as well as for treatment of progressive Hodgkin’s lymphoma. [8]